Demographics and disease characteristics of patients with PN symptoms at study entry
| . | Cohort 1 . | Cohort 2 . | Total (n = 49) . | |
|---|---|---|---|---|
| Zanubrutinib (n = 24) . | Ibrutinib (n = 22) . | Zanubrutinib (n = 3) . | ||
| Age, median (range), y | 69.5 (50-87) | 68 (57-83) | 70 (57-85) | 69 (50-87) |
| Male sex, n (%) | 15 (62.5) | 14 (63.6) | 3 (100) | 32 (65.3) |
| Prior lines of therapy, n (%) | ||||
| 0 | 6 (25.0) | 4 (18.2) | 1 (33.3) | 11 (22.4) |
| 1-3 | 15 (62.5) | 16 (72.7) | 2 (66.7) | 33 (67.3) |
| >3 | 3 (12.5) | 2 (9.1) | 0 | 5 (10.2) |
| Genotype by NGS, n (%) | ||||
| CXCR4WT | 18 (75.0) | 15 (68.2) | 3 (100) | 36 (73.5) |
| CXCR4MUT | 6 (25.0) | 5 (22.7) | 0 | 11 (22.4) |
| CXCR4FS | 4 (16.7) | 3 (13.6) | 0 | 7 (14.3) |
| CXCR4NS | 2 (8.3) | 2 (9.1) | 0 | 4 (8.2) |
| Unknown | 0 | 2 (9.1) | 0 | 2 (4.1) |
| Baseline IgM (central laboratory), median (range), g/L | 32.4 (6.7-68.9) | 21 (6.8-54.9) | 24 (13.8-42.5) | 26 (6.72-68.9) |
| Baseline anti-MAG Ab, median (range), TU | 70 (1 to >70 000) | 138 (9 to >70 000) | 70 (44-1545) | 85 (1 to >70 000) |
| Anti-MAG Ab elevation (>999 TU) at baseline, n (%) | 2 (8.3) | 7 (31.8) | 1 (33.3) | 10 (20.4) |
| . | Cohort 1 . | Cohort 2 . | Total (n = 49) . | |
|---|---|---|---|---|
| Zanubrutinib (n = 24) . | Ibrutinib (n = 22) . | Zanubrutinib (n = 3) . | ||
| Age, median (range), y | 69.5 (50-87) | 68 (57-83) | 70 (57-85) | 69 (50-87) |
| Male sex, n (%) | 15 (62.5) | 14 (63.6) | 3 (100) | 32 (65.3) |
| Prior lines of therapy, n (%) | ||||
| 0 | 6 (25.0) | 4 (18.2) | 1 (33.3) | 11 (22.4) |
| 1-3 | 15 (62.5) | 16 (72.7) | 2 (66.7) | 33 (67.3) |
| >3 | 3 (12.5) | 2 (9.1) | 0 | 5 (10.2) |
| Genotype by NGS, n (%) | ||||
| CXCR4WT | 18 (75.0) | 15 (68.2) | 3 (100) | 36 (73.5) |
| CXCR4MUT | 6 (25.0) | 5 (22.7) | 0 | 11 (22.4) |
| CXCR4FS | 4 (16.7) | 3 (13.6) | 0 | 7 (14.3) |
| CXCR4NS | 2 (8.3) | 2 (9.1) | 0 | 4 (8.2) |
| Unknown | 0 | 2 (9.1) | 0 | 2 (4.1) |
| Baseline IgM (central laboratory), median (range), g/L | 32.4 (6.7-68.9) | 21 (6.8-54.9) | 24 (13.8-42.5) | 26 (6.72-68.9) |
| Baseline anti-MAG Ab, median (range), TU | 70 (1 to >70 000) | 138 (9 to >70 000) | 70 (44-1545) | 85 (1 to >70 000) |
| Anti-MAG Ab elevation (>999 TU) at baseline, n (%) | 2 (8.3) | 7 (31.8) | 1 (33.3) | 10 (20.4) |
Ab, antibody; FS, frameshift; MUT, mutated; NGS, next-generation sequencing; NS, nonsense; WT, wild type.